Keywords: lilly, initiates, ph, iii, gbm, enzastaurin, trial

Lilly initiates Ph III GBM Enzastaurin trial

Article | 20 March 2006

Print This

US drug major Eli Lilly has initiated a Phase III study of enzastaurin, its investigational, targeted oral agent, in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in